Loading...
•
Dec 31, 2019
ADMA Biologics Q4 2019 Earnings Report
ADMA Biologics reported Q4 2019 earnings with a revenue increase of 197% compared to Q4 2018 and a net loss decrease of $7.4 million.
Key Takeaways
ADMA Biologics reported a significant increase in revenue for Q4 2019, driven by the commercial sales of ASCENIV and the relaunch of BIVIGAM. The company also strengthened its balance sheet through a public offering, leading to an improved working capital position.
Total revenues for Q4 2019 were $12.0 million, a 197% increase over Q4 2018.
ASCENIV sales started in October 2019, contributing to the revenue increase.
The commercial relaunch of BIVIGAM occurred in August 2019, also boosting revenue.
Net loss for Q4 2019 decreased to $10.6 million, compared to $18.0 million in Q4 2018.
Forward Guidance
The press release contains forward-looking statements regarding future revenues, demand for therapeutic products, fractionation plant turnaround, expansion of plasma collection center network, and research and development activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...